Chordia Therapeutics Past Earnings Performance

Past criteria checks 0/6

Chordia Therapeutics's earnings have been declining at an average annual rate of -918.1%, while the Biotechs industry saw earnings growing at 11.6% annually. Revenues have been declining at an average rate of 100% per year.

Key information

-918.1%

Earnings growth rate

-886.2%

EPS growth rate

Biotechs Industry Growth	31.9%
Revenue growth rate	-100.0%
Return on equity	-43.9%
Net Margin	n/a
Next Earnings Update	14 Jan 2025

Recent past performance updates

Recent updates

We're Hopeful That Chordia Therapeutics (TSE:190A) Will Use Its Cash Wisely

Dec 19

Revenue & Expenses Breakdown

How Chordia Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:190A Revenue, expenses and earnings (JPY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Aug 24	0	-1,827	302	1,500
31 Aug 23	2,500	223	291	1,997

Quality Earnings: 190A is currently unprofitable.

Growing Profit Margin: 190A is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Unable to establish if 190A's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare 190A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 190A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-36.8%).

Return on Equity

High ROE: 190A has a negative Return on Equity (-43.91%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 18:30
End of Day Share Price	2024/12/27 00:00
Earnings	2024/08/31
Annual Earnings	2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chordia Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution